<DOC>
	<DOC>NCT00912899</DOC>
	<brief_summary>This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety &amp; tolerability of noscapine HCl in patients with advanced multiple myeloma</brief_summary>
	<brief_title>A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Noscapine</mesh_term>
	<criteria>Advanced Multiple Myeloma. Progression after ≥ 2 lines of prior therapy, including at least one steroid, one immunomodulatory agent (iMID), one alkylator, and bortezomib (VELCADE®). ECOG performance status of either 0 or 1. Prior chemotherapy with antimicrotubule agents Metastasis involving the brain or spinal cord Clinically significant lung or heart disease Abnormal electrocardiogram Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria. Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Refractory Multiple Myeloma</keyword>
	<keyword>CB3304</keyword>
	<keyword>Noscapine HCl</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>